What is NICE?

NICE guidance helps health and social care professionals deliver the best possible care based on the best available evidence. This guidance supports healthcare professionals and others to make sure that the care they provide is of the best possible quality and offers the best value for money. The guidance is for the NHS, local authorities, charities, and anyone with a responsibility for commissioning or providing healthcare, public health or social care services. We also support these groups in putting our guidance into practice.

Saturday, 20 July 2013

Give vulnerable children best possible start in life, says NICE

The social and emotional wellbeing of vulnerable children under 5 should be at the heart of early intervention services so all children have a fair chance to succeed in later life, new NICE draft guidance recommends.
Draft recommendations issued for public consultation today (20 April) focus on the importance of better coordinated strategic and local early years services, which include home visiting, early education and childcare, to support all families and children during their early years.



NICE Citizens Council publishes final report on development of social care guidance

The Citizens Council, which advises the National Institute for Health and Care Excellence, has published its final report on factors that it believes should be considered when NICE develops social care guidance.
At a two-day meeting in early 2013, the 30 members of the public who make up the Citizens Council discussed which aspects of benefit, cost, and need NICE should bear in mind when producing guidance on social care. NICE assumed responsibility for developing guidance and quality standards for social care from April 2013.
As this is a new area of work for NICE, the Council's advice is informing the development of processes and methods, and action is already being taken based on the Council's conclusions.

Thursday, 4 July 2013

NICE plans to recommend a new treatment for children with bipolar disorder

NICE, the health and social care guidance body, has issued new draft guidance proposing to recommend aripiprazole (Abilify, Otsuka Pharmaceuticals Europe), for treating moderate to severe manic episodes in adolescents aged 13 and older with bipolar I disorder1.
Commenting on the draft guidance, Professor Carole Longson, Director, Centre for Health Technology Evaluation, said. “Bipolar disorder is a serious mental health condition which is characterised by episodes of mania and depression. During a manic episode, the young person usually experiences irritability, poor concentration, little need for sleep and poor temper control. They may also feel over-confident and be driven to take unnecessary risks.